Your first 90 days
Your first 90 days on Dawnzera for hereditary angioedema (HAE)
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Dawnzera has no safety program forms, no required blood tests and no dose build-up. The first dose waits on an enrollment form, an insurance approval, injection training and a call with the specialty pharmacy. After that comes one autoinjector every 4 weeks, or every 8 weeks if the prescriber chooses that schedule. This page lays out those weeks from the FDA label, Ionis's own Dawnzera pages and one insurer's written rules.
What has to happen before the first bottle ships
Dawnzera has no REMS, so the first dose waits on the enrollment form, a prior authorization, injection training and a pharmacy call. These are the 8 things in the way, in order.
The Enrollment and Prescription Form
Ionis says your doctor completes the Dawnzera Patient Enrollment and Prescription Form, and you give consent.
- You can sign the form in the office, enroll at DAWNZERA.com/Enroll or call 1-844-444-4305.Ionis Every Step brochure
A Welcome Kit and a call
After you sign up, Ionis sends a Welcome Kit and your Patient Education Manager calls to schedule injection training.
- The kit holds a practice pen so you can get to know the autoinjector.Getting started guide
The insurance approval
Ionis says your doctor's office may need to send information to your plan to get Dawnzera approved.
- It helps if the office knows how many attacks you have each month, how bad they are and how long they last.Getting started guide
What one plan asks for
Cigna asks for lab results showing HAE type I or type II, and an allergist, immunologist or HAE specialist.
- Its employer plans also ask that you tried Haegarda and Takhzyro first.Cigna policy
Free medicine while coverage is decided
The enrollment form signs insured patients up for Quick Start unless the prescriber opts out.
- Quick Start provides free Dawnzera during the insurance approval process, once the prior authorization information is in.Enrollment form
Injection training
The Patient Information says your healthcare provider will show you and your caregiver how to inject the first time.
- The Instructions for Use say to read them before the first dose and at each refill.FDA label
A call with the specialty pharmacy
The Ionis Every Step Specialty Pharmacy calls from 1-844-444-4305 to set up delivery.
- Ionis says Dawnzera will not ship until you have spoken with the pharmacy about cost and delivery.HCP starting patients
A medicine list for your care team
The Patient Information asks you to tell your provider about every medicine, vitamin and herbal supplement.
- The label says no clinical drug interaction studies have been done with Dawnzera.FDA label
The days that matter
Counted from the first dose, with doses every 4 weeks, the every-8-week dosage the label says may be considered and a delivery before each dose. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Enrollment form, then the benefits check
The office completes the Enrollment and Prescription Form and faxes it to Ionis Every Step.
- Ionis then confirms your benefits and the criteria your plan sets.
- No source says how long approval takes.
The Patient Education Manager calls
Ionis says you get a Welcome Kit and a call from your Patient Education Manager, who schedules injection training.
- The kit includes a practice pen for getting to know the autoinjector.
The pharmacy call and delivery
The specialty pharmacy calls to talk about cost and set up delivery to your door.
- Ionis asks you to save 1-844-444-4305 so you recognize and answer the call.
First dose
One 80mg autoinjector, into the belly or the front of the thigh.
- The instructions say to take it out of the refrigerator 30 minutes before the shot and leave it in its carton to warm.
Next delivery, one autoinjector at a time
The prescription form writes each fill as one single-dose autoinjector, with refills.
- On the every-4-week schedule, that means a delivery about every 4 weeks.
The first lab check in the trial
Dawnzera lowers prekallikrein, a protein behind HAE swelling.
- In the label's main trial, prekallikrein was down 48% on average at week 4, the first time it was measured.
Second dose, then every 4 weeks
On the every-4-week schedule, doses fall on days 29, 57 and 85.
- If a dose is missed, the label says to give it as soon as possible and count the next dose from that day.
Next delivery, number 2
Second dose, number 2
Second dose on the every-8-week schedule
If the prescription is every 8 weeks, the second dose falls on day 57.
- The label says every 8 weeks may be considered and gives no rule for who should use it.
Next delivery, number 3
Second dose, number 3
Three months in
The main trial counted attacks for 24 weeks, so 3 months is about halfway through that period.
- The allergist decides whether the schedule stays the same.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Dawnzera label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated August 31, 2026, read from the FDA's label database today. FDA label
- August 2025
The FDA first approved Dawnzera on August 21st to prevent HAE attacks in people 12 and older. The approval letter requires Ionis to finish 2 extension trials that look for liver injury, and a 2-year rat study of tumor risk.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- The dose
The label's recommended dose is 80mg under the skin every 4 weeks, from age 12.
- It says 80mg every 8 weeks may also be considered.
- The prescriber decides which schedule you use.FDA label
- How the two schedules did in the trial
In the main trial, the attack rate was 81% lower than placebo on the every-4-week dose.
- On the every-8-week dose it was 55% lower than placebo.FDA label
- Who gives the shot
The label says Dawnzera is meant for self-injection or injection by a caregiver, after training.
- It has not been shown to be safe and effective in children under 12.FDA label
- Where the shot goes
Use the belly or the front of the thighs, at least 2 inches from the belly button.
- The instructions say only a caregiver or healthcare provider may use the back of the upper arm.FDA label
- Skin to avoid
The instructions say not to inject into skin that is bruised, tender, red or hard.
- They also rule out scars and damaged skin.FDA label
- If a dose is missed
The Patient Information says to take a missed dose as soon as possible.
- After that, the regular schedule of every 4 or every 8 weeks is counted from the date of that dose.FDA label
- It prevents attacks, it does not treat one
The label approves Dawnzera only to prevent HAE attacks.
- In the main trial, everyone could still use rescue medicine for breakthrough attacks.
- The allergist decides which on-demand medicine you keep on hand.FDA label
- Storage
Keep the autoinjector in the refrigerator at 36°F to 46°F (2°C to 8°C), in its original carton.
- The label says not to freeze it or expose it to heat, and to protect it from direct light.FDA label
- Out of the refrigerator
If needed, Dawnzera can stay at room temperature up to 86°F (30°C), in the original carton, for up to 6 weeks.
- The label says to throw it away if it is not used within those 6 weeks.FDA label
- Warming and checking before the shot
Let the autoinjector warm in its carton for 30 minutes, without a microwave or hot water.
- The medicine should look clear and colorless to yellow, and air bubbles are normal.
- The instructions say not to use one that is cloudy, expired or damaged.FDA label
- Giving the full dose
The instructions say to push firmly, listen for a click and hold the autoinjector against the skin for 10 seconds.
- The orange plunger rod should fill the whole viewing window.
- If it does not, the instructions say to contact your healthcare provider.FDA label
- Used autoinjectors
Put each used autoinjector in a sharps container right away, and never reuse it.
- The instructions describe a heavy-duty plastic household container with a tight lid if you do not have an FDA-cleared one.FDA label
- Liver problems
The label does not recommend Dawnzera for people with moderate or severe liver impairment, and says it was not studied in them.
- No dose change is needed for mild liver impairment.FDA label
- Blood test changes seen in trials
The label sets no routine blood tests.
- In the main trial, platelet counts fell 9.6% on average on the every-4-week dose, against 1.4% on placebo.
- Liver enzymes also rose, with the increases generally below 3 times the upper limit of normal.FDA label
- Pregnancy and breastfeeding
There are no data on Dawnzera in pregnant women, and it is not known whether it passes into breast milk.
- The Patient Information asks you to tell your provider if you become pregnant during treatment.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of a serious allergic reaction
Rash, trouble breathing, fainting, dizziness or feeling lightheaded, swelling of the face, lips or tongue, chest pain or itching.
- The Patient Information says to stop Dawnzera and call your provider or go to the nearest emergency room right away.
- Allergic reactions, including anaphylaxis, occurred in clinical trials.FDA label
Reactions where the shot went in
Redness, pain, itching, bruising or swelling at the injection site was the most common side effect.
- It occurred in 24% of people on the every-4-week dose against 5% on placebo.
- The label says all were mild and most cleared without treatment.FDA label
Other common side effects
Upper respiratory infections, urinary tract infections and belly discomfort were the other common side effects.
- The Patient Information says to tell your provider about any side effect that bothers you or does not go away.FDA label
Attacks that keep coming
In the main trial, 53% on the every-4-week dose had no attacks from week 4 to week 24.
- That compares with 35% on the every-8-week dose and 9% on placebo, so breakthrough attacks can still happen.
- The allergist decides what they mean for the plan.FDA label
A dose that may not have gone in
If the orange plunger rod does not fill the viewing window, you may not have received the full dose.
- The instructions say to contact your healthcare provider if this happens.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedCigna asks for a functional C1-INH level under 50% of normal and a low C4 level, each with lab documentation. It also wants an allergist, immunologist or HAE specialist, and a patient aged 12 or older. The office sends both lab reports.Cigna policy
- The plan wants other medicines tried firstCigna's employer plans ask that the patient has tried both Haegarda and Takhzyro, or is already receiving Dawnzera. Other plans set their own lists.Cigna policy
- HAE with normal C1-INHCigna's policy says HAE with normal C1-INH, also called type III, does not meet its diagnosis requirement. That holds for first approvals and for renewals.Cigna policy
- Another preventive medicine at the same timeCigna lists Dawnzera used with other preventive HAE medicines, such as Andembry, Cinryze, Haegarda, Orladeyo or Takhzyro, as not medically necessary. Medicines that treat an attack, or prevent one around a procedure, are allowed.Cigna policy
- A dose the plan will not coverCigna approves 80mg no more often than every 4 weeks. Other doses go to case-by-case review by a Cigna clinician.Cigna policy
- An appeal after a denialIonis tells offices to read the plan's reason for the denial and ask for a peer-to-peer review quickly. Its prescriber site offers a sample Letter of Appeal, and Ionis Every Step helps with appeals at 1-844-444-4305. The office files the appeal.HCP starting patients
- The medicine has not shippedIonis says Dawnzera will not ship until you speak with the Ionis Every Step Specialty Pharmacy about cost and delivery. The pharmacy calls from 1-844-444-4305, and Ionis suggests saving that number in your phone.HCP starting patients
- A copay you cannot payWith commercial insurance, Ionis Every Step says you may pay as little as $0 for each prescription. People who use Medicare, Medicaid, TRICARE, VA or other government programs for medicine costs are excluded. Ionis also runs a Patient Assistance Program for people without affordable insurance coverage.Ionis Every Step brochure
- A gap in insurance coverageIonis says its Bridge program can give a short-term supply at no cost during a temporary gap in commercial insurance. You have to be eligible, and terms apply. Ionis Every Step answers questions at 1-844-444-4305.Ionis Every Step brochure
Cigna prior authorization policy, September 15, 2026
- Age 12 or older
- HAE type I or type II, with a functional C1-INH protein level under 50% of normal at baseline, with lab documentation
- A serum C4 level below normal at baseline, with lab documentation
- HAE with normal C1-INH, also called type III, does not meet the diagnosis requirement
- Prescribed by or in consultation with an allergist, immunologist or a physician who specializes in HAE
- On employer plans, both Haegarda and Takhzyro tried first, unless the patient is already receiving Dawnzera
- A dose of 80mg no more often than every 4 weeks
- Not used together with another preventive HAE medicine such as Andembry, Cinryze, Haegarda, Orladeyo or Takhzyro
Approval length. Approved a year at a time. Renewal asks for HAE type I or II and a favorable response, such as fewer, milder or shorter attacks.
This version took effect September 15, 2026 and made no criteria changes. It cites the August 2025 prescribing information, and the label on DailyMed is marked revised September 2025 with the same dose. The step through Haegarda and Takhzyro was added for employer plans in March 2026. Other plans set their own criteria. It is here as an example, not as a rule. Cigna policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A Patient Education Manager who explains what happens after the prescription and teaches you how to use Dawnzera
- Work with your doctor and your insurance plan to help get Dawnzera covered
- A copay program where a commercially insured patient may pay as little as $0 out of pocket for each prescription
- No copay help for anyone who uses Medicare, Medicaid, TRICARE, Department of Defense, VA or other government programs for medicine costs
- Delivery to your door from the Ionis Every Step Specialty Pharmacy
- DAWNZERA Direct, a digital companion for refill scheduling, status updates and a swell diary
- Quick Start, a shipment of free medicine if insurance coverage is delayed Ionis Every Step brochure
- Bridge, a short-term supply at no cost during a temporary gap in commercial insurance, for people who are eligible Ionis Every Step brochure
- A Patient Assistance Program that provides Dawnzera at no cost to eligible people without affordable insurance, with a financial application and a yearly reapplication Ionis Every Step brochure
- A Free Trial Program, a one-time single dose at no charge for people new to Dawnzera, including people with Medicare and Medicaid Enrollment form
Details as the drugmaker publishes them. Ionis Every Step
Five questions for the pharmacist or the support line
- When will each autoinjector ship, and how do I schedule the next delivery?
- What do I do if a shipment arrives warm, or I lose track of how long one sat out of the refrigerator?
- Is my prescription written for every 4 weeks or every 8 weeks?
- Where can I get a sharps container for used autoinjectors?
- Which on-demand HAE medicine do I keep at home, and is that prescription current?
Questions people ask in the first weeks
How often is Dawnzera given?
The label's recommended dose is 80mg every 4 weeks, from age 12. It says 80mg every 8 weeks may also be considered. The prescriber decides which schedule you use.
Can I give Dawnzera myself?
Yes, the label says Dawnzera is meant for self-injection or injection by a caregiver, after training. You can use the belly or the front of the thigh. Only a caregiver or healthcare provider may use the back of the upper arm.
What if I miss a dose of Dawnzera?
The Patient Information says to take the missed dose as soon as possible. The regular schedule, every 4 or every 8 weeks, is then counted from the date of that dose.
Does Dawnzera treat an HAE attack?
No, the label approves it only to prevent attacks. In the main trial, everyone could use rescue medicine for breakthrough attacks. The allergist or immunologist decides which on-demand medicine you keep on hand.
Do I need blood tests on Dawnzera?
No, the label sets no routine blood tests. In the main trial, platelet counts fell 9.6% on average on the every-4-week dose, and liver enzyme increases were also seen. The label does not recommend Dawnzera for people with moderate or severe liver impairment.
How do I store Dawnzera?
In the refrigerator at 36°F to 46°F (2°C to 8°C), in the original carton, never frozen. If needed, it can stay at room temperature up to 86°F (30°C) for up to 6 weeks. The label says to throw it away after that.
Does Medicare work with the Dawnzera copay program?
No, the copay program excludes anyone who uses Medicare, Medicaid, TRICARE, VA or other government programs for medicine costs. The enrollment form describes a Free Trial Program, a one-time single dose for people new to Dawnzera. It says people with Medicare and Medicaid are eligible. Its Patient Assistance Program is for people without affordable insurance coverage.
Free email alert
Hear when the Dawnzera label changes
One email the day the FDA revises the Dawnzera label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Dawnzera only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Hereditary angioedema (HAE) for new trials, FDA decisions and label changes for every treatment.
Sources
- DailyMed - DAWNZERA- donidalorsen injection, solution (prescribing information revised 9/2025, Patient Information issued 08/2025, Instructions for Use approved 08/2025), Ionis Pharmaceuticals Inc., via DailyMed, August 31, 2026.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, November 11, 2026.
- Sign Up for Ionis Every Step™ | DAWNZERA™ (donidalorsen), Ionis Pharmaceuticals, November 11, 2026.
- Ionis Every Step brochure: Let's take this step by step, together (US-DONI-2500102 v1.0 08/2025), Ionis Pharmaceuticals, November 11, 2026.
- Getting Started With DAWNZERA™ (donidalorsen) (US-DONI-2500216 v1.0 08/2025), Ionis Pharmaceuticals, November 11, 2026.
- DAWNZERA Patient Enrollment and Prescription Form (US-DONI-2500004 v2.0 08/2025), Ionis Pharmaceuticals, November 11, 2026.
- Getting Patients Started on DAWNZERA™ (donidalorsen), Ionis Pharmaceuticals, November 11, 2026.
- Ionis Every Step™ | DAWNZERA™ (donidalorsen), Ionis Pharmaceuticals, November 11, 2026.
- Hereditary Angioedema - Dawnzera, Drug Coverage Policy IP0761, Cigna, September 15, 2026.
- NDA 219407 approval letter, Dawnzera (donidalorsen) solution for injection, FDA, August 21, 2025.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing allergist or immunologist. Found an error? Use the report link in the footer and it will be checked against the source.